Porphyromonas uenonis cDNA and Antigen

Porphyromonas uenonis is a Gram-negative, anaerobic, rod-shaped bacterium. It was first isolated from the oral cavity of an adult male in 1999 and is the only species classified in the genus Porphyromonas. P. uenonis is a part of the human oral microbiome, where it is found in low concentrations and is associated with periodontal diseases. It is also found in the gastrointestinal tract of humans and is associated with inflammatory bowel disease. P. uenonis can produce proteolytic enzymes, which can degrade proteins and cause tissue destruction. Additionally, P. uenonis is known to produce a variety of virulence factors like adhesins, hemolysins and biofilm formation, which can contribute to the pathogenesis of periodontal diseases.Porphyromonas uenonis expresses several key immunogenic antigens that are of interest to researchers and healthcare professionals.

One of these important antigens is the 23 kDa lipoprotein PG3, which has been shown to stimulate an immune response in individuals with periodontal disease. Another key antigen expressed by Porphyromonas uenonis is the 75 kDa protein PG4, which has also been linked to the immune response in patients with this condition.

The 47 kDa antigen PG97 is another important antigen expressed by Porphyromonasuenonis. This antigen has been shown to play a role in the host immune response to the bacterium. Interestingly, the bacterium also expresses another 47 kDa antigen, suggesting that this antigen may play a crucial role in the pathogenicity of the bacterium.

Porphyromonas uenonis also expresses several important receptor antigens, including the surface antigen and the surface antigen BspA. These receptor antigens have been shown to be involved in the interaction between the bacterium and the host.

Overall, understanding the key antigens and receptor antigens expressed by Porphyromonas uenonis is important for developing effective strategies to diagnose and treat periodontal disease.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

The cDNA (complementary DNA) and recombinant antigen of P. uenonis can be used in various applications for diagnosis, research, and vaccine development.

Diagnostic Tests: cDNA of P. uenonis can be used in molecular diagnostic tests to detect the presence of the bacterium in a patient’s sample. This can be done by amplifying a specific genetic target using polymerase chain reaction (PCR) and detecting the amplified product using fluorescence or other methods.

Research: cDNA of P. uenonis can be used in research studies to investigate the genetic characteristics and pathogenesis of the bacterium. Recombinant antigens can also be used to study the immune response to P. uenonis infections, to identify potential vaccine candidates, and to develop new diagnostic tests.

Vaccine Development: Recombinant antigens of P. uenonis can be used to develop vaccines against the bacterium. These vaccines can stimulate the production of specific antibodies that recognize and neutralize P. uenonis.